Organogenesis Holdings (ORGO) Income towards Parent Company (2016 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Income towards Parent Company of -$53.2 million for Q1 2026, down 182.1% year-over-year from $64.7 million in Q1 2025, and down 208.25% quarter-over-quarter from $49.1 million in Q4 2025.
Organogenesis Holdings (ORGO) Income towards Parent Company (2016 - 2026) Analysis & Trends
Organogenesis Holdings' Income towards Parent Company history runs 11 years deep, the most recent figure standing at -$53.2 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 182.1% year-over-year to -$53.2 million; the TTM figure through Mar 2026 stood at $8.1 million (up 151.15% YoY), while the FY2025 annual figure was $42.4 million, up 4828.8% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$53.2 million, down from $49.1 million in the prior quarter.
- The five-year high for Income towards Parent Company was $49.1 million in Q4 2025, with the low at -$53.2 million in Q1 2026.
- The 5-year median for Income towards Parent Company is $1.4 million (2023), against an average of $743058.8.
- The sharpest annual moves came in 2023 and 2025: Income towards Parent Company jumped 1373.02% in 2023, then tumbled 797.29% in 2025.
- Organogenesis Holdings' Income towards Parent Company stood at $7.5 million in 2022, then slumped by 80.71% to $1.4 million in 2023, then soared by 431.37% to $7.7 million in 2024, then jumped by 539.97% to $49.1 million in 2025, then tumbled by 208.25% to -$53.2 million in 2026.
- Business Quant data shows ORGO's Income towards Parent Company at -$53.2 million in Q1 2026, $49.1 million in Q4 2025, and $21.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Organogenesis Holdings | 241.78 Mn | 194.94 Mn | 20.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -96.27 Mn |
| Mar 31, 2026 | -53.16 Mn |
| Dec 31, 2025 | 49.11 Mn |
| Sep 30, 2025 | 21.57 Mn |
| Jun 30, 2025 | -9.39 Mn |
| Mar 31, 2025 | -18.84 Mn |
| Dec 31, 2024 | 7.67 Mn |
| Sep 30, 2024 | 12.33 Mn |
| Jun 30, 2024 | -17.04 Mn |
| Mar 31, 2024 | -2.10 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 30, 2023 | 3.17 Mn |
| Jun 30, 2023 | 5.32 Mn |
| Mar 31, 2023 | -2.97 Mn |
| Dec 31, 2022 | 7.49 Mn |
| Sep 30, 2022 | 215,000.00 |
| Jun 30, 2022 | 8.74 Mn |
| Mar 31, 2022 | -913,000.00 |
| Dec 31, 2021 | 19.02 Mn |
| Sep 30, 2021 | 12.58 Mn |